What is LGD 4033 SARM? A Comprehensive LGD 4033 Review
LGD 4033 (Ligandrol/Anabolicum)
LGD 4033 is a Selective Androgen Receptor Modulator (SARM) that is also known by the names Ligandrol and Anabolicum. LGD 4033 (Ligandrol/Anabolicum) is known for its ability to promote an increase in lean muscle mass which doesn’t accompany the side effects associated with steroidal SARMs or anabolic-androgenic steroids (AAS). This is a property that makes LGD 4033 (Ligandrol/Anabolicum) of strong interest within the medical and pharmaceutical industries, as well as with athletes, bodybuilders, and individuals interested in performance enhancement.
LGD4033 (Ligandrol/Anabolicum) behaves similarly to an anabolic steroid in that it can quickly promote an increase of lean muscle mass while promoting a reduction in body fat.
The pharmaceutical industry classifies LGD 4033 (Ligandrol/Anabolicum) as a SARM. Although this chemical was first discovered and made by Ligand Pharmaceuticals, the development of LGD 4033 can be credited to Viking Therapeutics, which is a separate organization.
In the Phase 1 clinical trial of 76 adult male humans in which the dose size was varied, a dose-dependent increase in lean body mass was observed with no significant adverse events over 21 days.
The Phase 2 clinical trial, initiated on 3 November 2016, consists of 120 patients recovering from hip fracture surgery. The randomized study participants will receive either a placebo or varying dose sizes of LGD 4033 over a period of 12 weeks, with improved lean body mass as the primary endpoint. Other endpoints include satisfactory results in terms of quality of life, safety, and pharmacokinetics.
In this Ligandrol review, we will describe LGD 4033 (Ligandrol) effects on the body, and why there are Ligandrol benefits when compared to traditional steroidal anabolic hormones (anabolic steroids).
LGD 4033 Dosage:
DISCLAIMER: ELV Bioscience does not provide medical advice, nor does ELV Bioscience condone or promote the usage of these investigative compounds. However, in our aggregation of anecdotal reports throughout the internet, compared with available clinical research, ELV Bioscience has summarized the following information:
The most popularly used dose of LGD 4033 (Ligandrol/Anabolicum) is between 1 and 10mg per day. Clinical trials studied doses lower than 1mg per day with favorable results and increases in lean body mass.
We’ve seen reports of serious athletes and bodybuilders report benefits from up to 20mg per day.
We’ve seen claims of favorable results in performance enhancement, as well as favorable outcomes in available clinical research when LGD 4033 (Ligandrol/Anabolicum) is administered to subjects for 8-12 weeks.
According to available research, LGD 4033 (Ligandrol/Anabolicum) will cause endogenous testosterone suppression on a dose-dependent basis. Therefore, we have seen courses of LGD 4033 (Ligandrol/Anabolicum) use followed by “post cycle therapy” protocols that utilize a combination of tamoxifen and clomiphene to aid in the restoration in natural testosterone production.
Uses of LGD 4033 SARM:
On a milligram for milligram basis, LGD 4033 (Ligandrol/Anabolicum) is the most anabolic SARM and one of the strongest SARMs in production at this time. Additionally, LGD 4033 (Ligandrol/Anabolicum) can create significant muscle growth without many of the adverse reactions related to anabolic steroid use. LGD 4033 (Ligandrol/Anabolicum) has also been shown and anecdotally reported, to increase healing potential not only for skeletal muscle but for joints and connective tissue as well.
These reports are summarized as follows:
We’ve seen many reports of LGD 4033 (Ligandrol/Anabolicum) being taken with MK677 (Ibutamoren/Nutrobal), creating an exceptionally synergistic combination for lean muscle growth and body fat loss. MK677 (Ibutamoren/Nutrobal) is an orally active, non-peptide growth hormone secretagogue initially created by Reverse Pharmacology. A secretagogue is a substance that causes the endogenous (the body’s own) release of another chemical or hormone. MK677 (Ibutamoren/Nutrobal ) signals the pituitary gland to secrete human growth hormone (HGH/Somatropin). Experiences with combining MK677 (Ibutamoren/Nutrobal) with LGD4033 (Ligandrol/Anabolicum) commonly report increases in strength, performance, muscle growth, body-fat loss, improved sleep, and faster recovery from exercise and certain injuries.
For further fat loss, muscle growth, and performance enhancement benefits, we’ve seen many reports of concurrent administration of GW501516 (Cardarine). GW501516 (Cardarine) is a PPARδ receptor agonist created by a collaboration between GlaxoSmithKline and Ligand Pharmaceuticals in the 1990s. Cardarine (Cardarine) was initially created to treat diabetes, dyslipidemia, obesity, and cardiovascular diseases.
Where to Buy LGD 4033 SARM?
ELV Bioscience has the USA manufactured and third-party laboratory tested SARMs and other research chemicals that meet the highest purity and quality standards. Any raw material that doesn’t meet our criteria of quality is rejected. The products sold on our website are for research purposes only.
We hope that this LGD 4033 review and LGD 4033 guide has helped you get a basic understanding of the LGD 4033 (Ligandrol/Anabolicum) SARM, its uses, benefits, clinical results, anecdotal results, and risks.
Basaria S1, Collins L, Dillon EL, Orwoll K, Storer TW, Miciek R, Ulloor J, Zhang A, Eder R, Zientek H, Gordon G, Kazmi S, Sheffield-Moore M, Bhasin S. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):87-95. doi: 10.1093/gerona/gls078. Epub 2012 Mar 28.
Ryan AM, Power DG, Daly L, et al. Cancer- associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc 2016; 75: 199–211.
Bhasin S, Calof OM, Storer TW, et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Practice Endocrinol Metab. 2006;2:146–159.
Dalton JT, Taylor RP, Mohler ML, Steiner MS. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Curr Opin Support Palliat Care. 2013 Dec;7(4):345-51. doi: 10.1097/SPC.0000000000000015. Review.
Basaria S, Collins L, Dillon EL, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2010;68(1):87-95.